Hyperbaric Oxygen Therapy for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Hyperbaric Oxygen Therapy for Health & Longevity

Created on 08/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A finite course of sessions in a pressurised chamber breathing pure oxygen. Beyond wound healing, gains in thinking, fitness, blood sugar handling and pain are mixed, and the boldest cell-ageing claims rest on markers never tied to real-world outcomes. Costs 150–200 hours and five figures, with predictable ear and vision effects and a small seizure chance. (Full Review)

Protocol

Standard longevity protocol
60 sessions over 12 weeks
Five days weekly; 90 minutes breathing 100% oxygen at 2.0 ATA with five-minute air breaks every 20 minutes
Alternative shorter protocol
40 sessions at 1.5 ATA
60 minutes per session; favoured in North American neurological practice. Not tested head-to-head against the 2.0 ATA course
Session continuity matters more than timing
Gaps over a few days generally made up
Effects follow cumulative session count; incomplete courses have not been shown effective. Morning sessions are usual
Time to effect
Cognitive Performance
60 sessions
Nothing measurable appears early; no protocol reports interim gains at 10 or 20 sessions
Cardiorespiratory Fitness and Cardiac Perfusion
12 weeks
Daily sessions; measured in sedentary adults over 64, so trained individuals may have less headroom
Insulin Sensitivity and Fasting Glucose
A single two-hour exposure
Whether the effect persists beyond hours, or occurs at all in metabolically healthy people, is untested

Benefits

Contraindications
  • Untreated pneumothorax of any size
  • Current or recent bleomycin exposure
  • Active, untreated bullous emphysema or a large unresolved lung bulla on imaging
  • Uncontrolled seizure disorder, or any seizure within the preceding 6 months
  • Untreated obstructive Eustachian tube disease or acute middle ear infection, until resolved
  • Pregnancy, outside emergency carbon monoxide poisoning
  • Severe uncontrolled congestive heart failure (New York Heart Association Class IV, or ejection fraction under 35%)
  • Uncontrolled high fever, until it resolves
    •
Key Interactions
  • Cisplatin and doxorubicin (chemotherapy agents), during active treatment
  • Disulfiram (alcohol-aversion drug)
  • Doxapram and other respiratory stimulants
  • Insulin and sulfonylureas (oral diabetes drugs)
  • Carbonic anhydrase inhibitors (acetazolamide)
  • Over-the-counter decongestants (pseudoephedrine, oxymetazoline)
  • Antioxidant supplements (high-dose vitamin C, vitamin E, N-acetylcysteine, alpha-lipoic acid)
  • Nitric oxide-supporting supplements (beetroot nitrate, L-Citrulline)
  • Other interventions (sauna, cold exposure, exercise)
    •

Risk & Side Effects

  • High: Middle ear barotrauma; reversible myopic shift; central nervous system oxygen toxicity seizures
  • Medium: Pulmonary oxygen toxicity symptoms; hypoglycaemia in insulin-treated diabetes; confinement anxiety
  • Low: Sinus and dental barotrauma; pulmonary barotrauma with cerebral arterial gas embolism; chamber fire
  • Speculative: Accelerated lens opacity with prolonged exposure; tumour-growth promotion

Monitoring

Marker Target Why
Capillary blood glucose (pre-session) Above 120 mg/dL (6.7 mmol/L) at chamber entry Prevents in-chamber hypoglycaemia
HbA1c 4.8–5.4% Baseline metabolic status and the benefit signal most likely to move
hs-CRP Under 0.5 mg/L Tracks the inflammatory tone the treatment is proposed to lower
Haemoglobin and full blood count Men 14.0–15.0 g/dL; women 13.0–14.5 g/dL Oxygen-carrying baseline and detection of unrelated anaemia
Spirometry (FEV1 and FVC) Both at or above 80% of predicted, ratio above 0.70 Excludes obstructive disease and air trapping before pressurisation
Cycloplegic refraction (spherical equivalent) No established target; track change from the individual’s own baseline, investigating shifts beyond 0.50 dioptres Detects the predictable myopic shift and cumulative oxygen dose
VO2max (maximal oxygen uptake) At or above the 75th percentile for age and sex The endpoint with the strongest link to all-cause mortality, and the trial’s primary outcome
Tympanometry Type A tracing (normal middle ear pressure and compliance) Predicts the commonest adverse event before it happens

Cadence: Full screening panel before session one. Capillary glucose before every session in anyone taking insulin or a sulfonylurea; ear examination repeats at any report of pain. Refraction, hs-CRP, spirometry and the exercise test repeat at course end, then at 6 and 12 months.

Qualitative Assessment

  • Sleep quality and time to fall asleep, recorded weekly rather than nightly
  • Daytime energy and post-session fatigue, which typically peaks in the first two weeks
  • Cognitive clarity in demanding tasks, particularly sustained attention and word-finding
  • Exercise tolerance — breathlessness at a fixed familiar effort is the most sensitive informal marker
  • Ear discomfort, facial pain, and any change in near or distance vision, logged every session
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.